BioNexus Gene Lab (BGLC) Stock Price, News & Analysis

Company Overview

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Key Stats

• Today's Range: $0.36 to $0.38
• 50-Day Range: $0.35 to $0.46
• 52-Week Range: $0.31 to $3.39
• Volume: 58,045 shs
• Average Volume: 629,476 shs
• Market Capitalization: $6.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BioNexus Gene Lab Stock Analysis - MarketRank™

BioNexus Gene Lab scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BioNexus Gene Lab.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

BioNexus Gene Lab has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.87% of the float of BioNexus Gene Lab has been sold short.

Short Interest Ratio / Days to Cover

BioNexus Gene Lab has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioNexus Gene Lab has recently decreased by 45.14%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioNexus Gene Lab does not currently pay a dividend.

Dividend Growth

BioNexus Gene Lab does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.87% of the float of BioNexus Gene Lab has been sold short.

Short Interest Ratio / Days to Cover

BioNexus Gene Lab has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioNexus Gene Lab has recently decreased by 45.14%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

BioNexus Gene Lab has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioNexus Gene Lab insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.02% of the stock of BioNexus Gene Lab is held by insiders.

Percentage Held by Institutions

Only 18.85% of the stock of BioNexus Gene Lab is held by institutions.

BGLC Stock Analysis - Frequently Asked Questions

How have BGLC shares performed this year?

BioNexus Gene Lab's stock was trading at $0.53 at the beginning of 2024. Since then, BGLC stock has decreased by 28.8% and is now trading at $0.3772.
View the best growth stocks for 2024 here.

How were BioNexus Gene Lab's earnings last quarter?

BioNexus Gene Lab Corp. (NASDAQ:BGLC) announced its quarterly earnings data on Wednesday, August, 14th. The company reported $0.01 earnings per share for the quarter. The business had revenue of $1.98 million for the quarter. BioNexus Gene Lab had a negative net margin of 24.01% and a negative trailing twelve-month return on equity of 23.07%.

When did BioNexus Gene Lab IPO?

BioNexus Gene Lab (BGLC) raised $5 million in an initial public offering (IPO) on Thursday, July 20th 2023. The company issued 1,300,000 shares at a price of $4.00 per share. Network 1 Financial Securities served as the underwriter for the IPO.

How do I buy shares of BioNexus Gene Lab?

Shares of BGLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of BioNexus Gene Lab own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioNexus Gene Lab investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 11/02/2024
• Next Earnings (Estimated): 11/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:BGLC
• CUSIP: N/A
• CIK: 1737523
• Web: www.bionexusgenelab.com
• Phone: 60-1-2212-6512
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-2,630,000.00
• Net Margins: -24.01%
• Pretax Margin: -22.96%
• Return on Equity: -23.07%
• Return on Assets: -19.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.61
• Quick Ratio: 4.87

Sales & Book Value

• Annual Sales: $9.18 million
• Price / Sales: 0.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.55 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 17,968,000
• Free Float: 17,605,000
• Market Cap: $6.78 million
• Optionable: Not Optionable
• Beta: 7.70